Novartis inked a big value-based pricing deal for its heart failure drug Entresto with Cigna and Aetna. After peak Hep C pricing, Entresto is the entrant that’s been keeping payers up at night. Novartis’ deal with Cigna ties pricing, in part, to hospital readmissions. Company execs have, in the past, talked about bundling remote monitoring services with their products, but it seems they’re not there yet.
- An Internet “doctor on call” entrepreneur on why the “Uber for doctors” startups are toast.
- Messing with AIDS activists and the United States Congress are one thing, but Martin Shkreli’s dig at Wu Tang Clan may have been a troll too far – now Ghostface Killah has the brahteur in his sights.
- The industry has been laboring to disassociate itself with Shkreli, but price hikes have, in fact, become a frequent tactic for keeping ornery investors at bay when innovation disappoints.
- Zenefits is the latest example of Silicon Valley’s hubris-fueled appetite for disruption running aground on the shoals of the heavily-regulated healthcare market.
- How Sanofi’s Afrezza inhalable insulin partnership went off the rails at a time when the company’s diabetes franchise is under pressure.
- Blink Health launched an app that promises to help consumers find cheap generics.
- The placebo effect can be effective treatment. Should placebos be prescribed?
- What’s holding up telesurgery? Cost, lagtime and security issues.
- A woman found out she was pregnant by way of Fitbit data.